{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:00:59Z","timestamp":1787313659515,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jhepr.2024.101287","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T12:40:26Z","timestamp":1732797626000},"page":"101287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phase II study with sorafenib plus radiotherapy for advanced HCC with portal and\/or hepatic vein tumor thrombosis"],"prefix":"10.1016","volume":"7","author":[{"given":"Yirui","family":"Zhai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxia","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-Xiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9158-8433","authenticated-orcid":false,"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.jhepr.2024.101287_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101287_bib2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ueg2.12098","article-title":"Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: prevalence and clinical significance","volume":"9","author":"Mahringer-Kunz","year":"2021","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhepr.2024.101287_bib3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular carcinoma","volume":"379","author":"Forner","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2024.101287_bib4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S2468-1253(19)30178-5","article-title":"Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west","volume":"4","author":"Lu","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101287_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249426","article-title":"The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: a cohort study","volume":"16","author":"Mahringer-Kunz","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2024.101287_bib6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2024.101287_bib7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1148\/radiol.211545","article-title":"Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial","volume":"303","author":"Zheng","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.jhepr.2024.101287_bib8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhepr.2024.101287_bib9","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2024.101287_bib10","doi-asserted-by":"crossref","first-page":"4073-4073","DOI":"10.1200\/JCO.2021.39.15_suppl.4073","volume":"39","author":"Breder","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2024.101287_bib11","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/jamasurg.2022.4702","article-title":"Phase 2 evaluation of neoadjuvant intensity-modulated radiotherapy in centrally located hepatocellular carcinoma: a nonrandomized controlled trial","volume":"157","author":"Wu","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jhepr.2024.101287_bib12","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ijrobp.2008.06.1486","article-title":"The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma","volume":"73","author":"Huang","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jhepr.2024.101287_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.canlet.2012.10.024","article-title":"Sorafenib potentiates irradiation effect in hepatocellular carcinoma in\u00a0vitro and in\u00a0vivo","volume":"329","author":"Yu","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jhepr.2024.101287_bib14","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2214\/AJR.06.0134","article-title":"Enhancing and expansile portal vein thrombosis: value in the diagnosis of hepatocellular carcinoma in patients with multiple hepatic lesions","volume":"188","author":"Shah","year":"2007","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.jhepr.2024.101287_bib15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1148\/radiol.2015150124","article-title":"Portal vein thrombosis in patients with hepatocellular carcinoma: diagnostic accuracy of gadoxetic acid-enhanced MR imaging","volume":"279","author":"Kim","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.jhepr.2024.101287_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2024.101287_bib17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000327577","article-title":"Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version","volume":"29","author":"Kudo","year":"2011","journal-title":"Dig Dis"},{"key":"10.1016\/j.jhepr.2024.101287_bib18","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/hepr.12697","article-title":"Report of the 19th follow-up survey of primary liver cancer in Japan","volume":"46","author":"Kudo","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhepr.2024.101287_bib19","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2024.101287_bib20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2024.101287_bib21","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2024.101287_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2024.101287_bib23","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1634\/theoncologist.2015-0196","article-title":"Sorafenib with and without transarterial chemoembolization for advanced hepatocellular carcinoma with main portal vein tumor thrombosis: a retrospective analysis","volume":"20","author":"Zhang","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.jhepr.2024.101287_bib24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5009\/gnl19367","article-title":"Comparison of sorafenib versus hepatic arterial infusion chemotherapy-based treatment for advanced hepatocellular carcinoma with portal vein tumor thrombosis","volume":"15","author":"Ahn","year":"2021","journal-title":"Gut Liver"},{"key":"10.1016\/j.jhepr.2024.101287_bib25","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2024.101287_bib26","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2024.101287_bib27","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019660","article-title":"Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"99","author":"Que","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhepr.2024.101287_bib28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13014-018-1136-5","article-title":"Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis","volume":"13","author":"Shui","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.jhepr.2024.101287_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257556","article-title":"Advanced radiotherapy technique in hepatocellular carcinoma with portal vein thrombosis: feasibility and clinical outcomes","volume":"16","author":"Khorprasert","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2024.101287_bib30","article-title":"Stereotactic Body Radiotherapy Vs Sorafenib Alone in Hepatocellular Carcinoma: The Nrg Oncology\/Rtog 1112 Phase 3 Randomized Clinical Trial","author":"Dawson","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhepr.2024.101287_bib31","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2147\/JHC.S464140","article-title":"Radiotherapy with targeted therapy or immune checkpoint inhibitors for hepatocellular carcinoma with hepatic vein and\/or inferior vena cava tumor thrombi","volume":"11","author":"Li","year":"2024","journal-title":"J\u00a0Hepatocell Carcinoma"},{"key":"10.1016\/j.jhepr.2024.101287_bib32","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101287_bib33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2024.101287_bib34","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2024.101287_bib35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2024.101287_bib36","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1200\/JCO.22.00620","article-title":"Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase III trial","volume":"41","author":"Qin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2024.101287_bib37","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2024.101287_bib38","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00280-018-3638-0","article-title":"Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis","volume":"82","author":"Choi","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jhepr.2024.101287_bib39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1245\/s10434-010-1321-8","article-title":"Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study","volume":"18","author":"Luo","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jhepr.2024.101287_bib40","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","article-title":"TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study","volume":"109","author":"Yuan","year":"2023","journal-title":"Int J Surg"},{"key":"10.1016\/j.jhepr.2024.101287_bib41","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/cncr.33677","article-title":"Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: a prospective randomized study","volume":"127","author":"Ding","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.jhepr.2024.101287_bib42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000486483","article-title":"Comparison of outcome of hepatic arterial infusion chemotherapy combined with radiotherapy and sorafenib for advanced hepatocellular carcinoma patients with major portal vein tumor thrombosis","volume":"94","author":"Kodama","year":"2018","journal-title":"Oncology"},{"key":"10.1016\/j.jhepr.2024.101287_bib43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2017.2303","article-title":"Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial","volume":"4","author":"Feng","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258955592400291X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258955592400291X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T20:28:50Z","timestamp":1741638530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258955592400291X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S258955592400291X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101287","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study with sorafenib plus radiotherapy for advanced HCC with portal and\/or hepatic vein tumor thrombosis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101287","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101287"}}